Loading
Loading
The wire
Updated weeklyCurated from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical context for researchers — not academic abstracts.
Items tracked
40
Sources
FDA · NEJM · STAT · Reuters
Whether Eli Lilly or Novo Nordisk gains more GLP-1 market share may come down to cost and prescriber preference rather than clinical differences. Lilly reported nearly $23 billion in Q2 revenue, up 48%, driven by Mounjaro and Zepbound, while its Foundayo pill posted $98 million in sales but trailed expectations and Novo's Wegovy pill. If you're choosing a GLP-1, compare coverage, cash cost, and pill-versus-injection access before committing.
Read source →The FDA has reversed a prior position on peptide compounding, with five key points shaping what the change means for access and prescribing. If you use a compounded peptide, check the FDA notice and ask your provider whether the reversal affects it.
Read source →Retatrutide remains an investigational peptide drug drawing trillion-dollar market expectations; this rundown covers five things to know before it reaches approval. If you're considering retatrutide, wait for official trial results and regulatory approval before sourcing or using it.
Read source →Lilly filed six lawsuits against U.S. sellers of black-market retatrutide and says it has referred hundreds of sellers to regulators and law enforcement. Retatrutide remains investigational and in Phase 3 obesity trials, so any product sold for human use is unapproved and unverified — if you see it offered for sale, don't use it, and report the seller.
Read source →Lilly filed six lawsuits seeking to shut down what it calls a black market for unapproved retatrutide. If you're considering retatrutide, verify the seller and watch for legal action that could affect availability.
Read source →This report examines dental problems nicknamed "Ozempic teeth" and muscle loss among the most-discussed GLP-1 side effects. If you use a GLP-1, monitor changes in your teeth and strength and discuss them with your clinician.
Read source →This roundup covers an ADA review of an incident involving police, a lawsuit tied to an obesity trial, and early access to retatrutide. If you're considering retatrutide, watch for verified trial access and legal or safety updates rather than relying on unapproved sources.
Read source →An FDA advisory panel backed six peptides for compounding, signalling support but not final FDA authorization. If you use compounded peptides, watch for the FDA's final decision before changing your source or treatment.
Read source →An FDA advisory panel recommended allowing compounding pharmacies to manufacture Epitalon and Semax, but narrowly voted against emideltide. The votes followed the panel's decision the day before to recommend four other peptides — if you use a compounded peptide, check which ones your pharmacy supplies and watch for the FDA's final decision, which isn't bound by the panel's recommendation.
Read source →FDA advisory committee members favored removing restrictions on the first seven peptides reviewed on day one of a closely watched compounding meeting. If you use compounded peptides, watch for the committee's final recommendations and any FDA action before changing your source.
Read source →An FDA advisory panel narrowly voted to allow compounding of BPC-157, KPV, and other previously restricted peptides — a policy win for HHS Secretary RFK Jr. If you use compounded peptides, watch for final FDA action and confirm your pharmacy follows current compounding rules before ordering.
Read source →The FDA's Pharmacy Compounding Advisory Committee (PCAC) added two more bulk drug substances to the 503A list, continuing a string of recent peptide-related compounding decisions. If you use compounded peptides, check with your prescriber or pharmacy on whether your specific substance is now on the 503A list before ordering.
Read source →The FDA's Pharmacy Compounding Advisory Committee approved four bulk drug substances for the 503A list, potentially expanding what eligible compounding pharmacies can legally prepare. Official FDA confirmation is still pending before these substances become available.
Read source →Eli Lilly reported that retatrutide met its co-primary endpoints in both TRIUMPH-2 and TRIUMPH-3, with average weight loss reaching roughly 45–50 lbs in TRIUMPH-2 and up to 55.8 lbs in TRIUMPH-3. With four TRIUMPH trials now reporting positive results, Lilly says it's on track to submit retatrutide to the FDA in Q1 2027.
Read source →In TRIUMPH-2, adults with obesity/overweight and type 2 diabetes lost an average of 12.7–20.8% of body weight at 80 weeks across retatrutide doses versus 4.0% on placebo, with HbA1c falling 1.4–1.6 points more than placebo. TRIUMPH-3, run in patients with a BMI of 35+ and established cardiovascular disease, showed 21.6–22.6% weight loss on the two higher doses; GI side effects — mainly diarrhea — drove most treatment discontinuations.
Read source →An FDA advisory committee met to decide whether compounding pharmacies should be allowed to produce seven peptides currently classified as unsafe for compounding. Early reports point to a split outcome — some peptides advancing, others rejected — with FDA staff maintaining safety-data objections even as several newly appointed panel members, some with reported conflicts of interest, pushed toward wider access.
Read source →Ahead of the FDA's peptide compounding panel, HHS Secretary Robert F. Kennedy Jr. argued that FDA-inspected compounding pharmacies are a safer path to these substances than grey- and black-market suppliers. FDA staff and other critics countered that manufacturing quality doesn't substitute for missing human safety data — a disagreement that will shape whether these peptides move toward mainstream pharmacy channels or stay confined to unregulated sources.
Read source →STAT's health-policy newsletter rounds up a busy week: the FDA's advisory panel on compounded peptides — with a UCSF pediatrics professor questioning whether these products should reach patients before safety evidence exists — plus separate movement on cancer-drug approvals, cardiometabolic trial data, and Merck testing an Ebola vaccine in an active DRC outbreak.
Read source →This episode of STAT's Readout LOUD podcast covers a STAT investigation into telehealth company LifeMD, where former employees allege GLP-1 prescribing decisions prioritized profit over patient safety, plus LifeMD's distribution partnership with Novo Nordisk. It also touches on the ongoing Eli Lilly–Novo Nordisk legal dispute over GLP-1 advertising claims, alongside a separate feature on rare-disease drug development.
Read source →New research highlights that older adults on GLP-1 drugs like tirzepatide can lose significant lean muscle mass — up to 40% of total weight lost on high-efficacy GLP-1s — raising frailty, malnutrition, and dehydration risks in patients who often start with limited muscle reserve. Clinicians are advised to intervene at the first sign of frailty, which comes as Medicare's new $50-a-month GLP-1 coverage carries no requirement to assess baseline muscle or bone status before prescribing.
Read source →SAHPRA, the Health Professions Council of South Africa, and the South African Pharmacy Council issued a joint recall of semaglutide, tirzepatide, and combination products compounded by pharmacy group iDexis, warning that continued use, prescribing, or dispensing poses a severe safety risk. The recall follows a High Court interim order — sought by Novo Nordisk — barring iDexis from manufacturing or selling unregistered semaglutide-containing medicines.
Read source →Eli Lilly detailed the new Medicare GLP-1 Bridge program, which took effect July 1, 2026 and lets eligible Part D beneficiaries access Foundayo (orforglipron) or Zepbound (tirzepatide) for weight management at a $50 monthly copay, subject to prior authorization and CMS clinical criteria. It's the first time Part D has broadly covered a GLP-1 specifically for overweight or obesity, with coverage running through December 31, 2027.
Read source →The FDA has removed Epitalon from its Category 2 'significant safety concerns' list and scheduled it for review by the Pharmacy Compounding Advisory Committee on July 24, 2026. The committee will evaluate safety, clinical utility, and suitability for pharmacy compounding — a positive recommendation could restore broader legitimate access to this tetrapeptide, which has decades of research behind its proposed telomere-lengthening and longevity effects.
Read source →A legal analysis of non-binding congressional appropriations riders flags several FDA-relevant directives: tackling counterfeit GLP-1 active ingredients and finished products imported from China, cracking down on compounded GLP-1s marketed through telehealth platforms, and clearing a backlog of warning-letter inspections at 503A and 503B compounding facilities. The riders aren't binding law, but the analysis argues they signal where congressional pressure on the FDA is headed next.
Read source →STAT News surveys the rapidly evolving GLP-1 weight loss market — Novo Nordisk's Wegovy and Eli Lilly's Zepbound remain dominant, but Pfizer, Amgen and others are racing to compete. The report covers what the current leaders are developing to hold their ground and where the next wave of innovation is headed.
Read source →Full Phase 3 TRIUMPH-1 data confirm retatrutide's headline weight loss figures — up to 30.3% average reduction — along with significant BMI improvements in patients with obesity or overweight. Detailed dosing and safety data presented alongside the topline numbers.
Read source →ADA 2026 coverage highlights next-generation GLP-1 developments including triple hormone receptor agonists and longer-acting formulations targeting monthly or less-frequent dosing. Full trial data still pending for most candidates.
Read source →STAT News traces BPC-157's origins in researcher Predrag Sikiric's lab through its current widespread use in fitness and biohacking communities. The article examines the gap between preclinical research interest and the absence of approved human studies, and BPC-157's regulatory grey-area status.
Read source →Eli Lilly announced that retatrutide met its primary endpoint in the TRIUMPH-1 Phase 3 obesity trial, with weight loss described as 'powerful' — initial release ahead of full data disclosure at ADA 2026.
Read source →New England Journal of Medicine publishes a comprehensive review of GLP-1 receptor agonists as incretin analogues, covering mechanism of action, cardiovascular outcomes data, and the expanding therapeutic role across obesity, T2DM, and metabolic disease.
Read source →New data from Lilly suggests patients who stop GLP-1 agonists regain significant weight, supporting the case for long-term maintenance dosing strategies rather than finite treatment courses.
Read source →Survodutide (GLP-1/glucagon dual agonist) achieved weight loss analysts described as 'Wegovy-like' and showed signs of muscle mass preservation — a potential differentiator from existing GLP-1 drugs.
Read source →The FDA has scheduled an advisory committee meeting on unapproved peptides used in compounding, signalling a potential policy shift following pressure from HHS Secretary RFK Jr.
Read source →Lilly's orforglipron became the first daily GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, removing a key compliance barrier of existing oral GLP-1 options.
Read source →STAT News opinion piece on the rise of consumer peptide use — arguing that distrust of pharmaceutical medicine is driving patients toward compounds with weaker evidence bases.
Read source →In a notable regulatory shift, the FDA has reclassified several unapproved peptides previously barred from compounding, ahead of a formal advisory committee review on their potential compounding use.
Read source →Retatrutide lowered HbA1c by an average of 1.7–2.0% across doses at 40 weeks in TRANSCEND-T2D-1, meeting its primary endpoint and advancing the compound toward potential regulatory submission.
Read source →Retatrutide's Phase 3 diabetes data show the compound may be a meaningful advance on existing GLP-1 drugs — cutting blood sugar and body weight significantly in the TRANSCEND-T2D-1 study.
Read source →Eli Lilly issued a public warning after uncovering significant levels of impurity in compounded tirzepatide products mixed with vitamin B12, urging patients to avoid these formulations.
Read source →Eli Lilly's Phase 3 TRIUMPH-4 trial, evaluating retatrutide in patients with obesity, reported positive topline results — further supporting retatrutide's position as the most potent weight-loss agent in late-stage development.
Read source →Methodology
Where this news comes from
Capital Peptides aggregates research news from primary sources only — FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted industry outlets (BioPharma Dive, STAT, AJMC, HCPLive). We summarize in plain English; click the source link to verify. No vendor sponsorship influences inclusion.